Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,448,849
  • Shares Outstanding, K 49,743
  • Annual Sales, $ 2,621 M
  • Annual Income, $ 252,020 K
  • 60-Month Beta 1.18
  • Price/Sales 4.30
  • Price/Cash Flow 20.81
  • Price/Book 5.92
Trade CRL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 2.11
  • Number of Estimates 9
  • High Estimate 2.25
  • Low Estimate 2.05
  • Prior Year 2.01
  • Growth Rate Est. (year over year) +4.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
219.79 +4.72%
on 10/29/20
257.88 -10.75%
on 11/09/20
+0.90 (+0.39%)
since 10/27/20
3-Month
197.33 +16.64%
on 09/04/20
257.88 -10.75%
on 11/09/20
+13.01 (+5.99%)
since 08/27/20
52-Week
95.58 +140.80%
on 03/19/20
257.88 -10.75%
on 11/09/20
+83.28 (+56.70%)
since 11/27/19

Most Recent Stories

More News
Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

CRL : 230.16 (+1.68%)
Charles River and PathoQuest Strengthen Strategic Partnership

PathoQuest SAS, a genomic expert company dedicated to quality control testing of biologics, and its strategic partner Charles River Laboratories International, Inc. (NYSE: CRL), announced today that it...

CRL : 230.16 (+1.68%)
SmarTrend Watching for Potential Rebound in Shares of Charles River La After 4.34% Loss

Charles River La (NYSE:CRL) traded in a range yesterday that spanned from a low of $224.31 to a high of $236.00. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $235.97...

CRL : 230.16 (+1.68%)
Charles River Laboratories to Present at Upcoming Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:

CRL : 230.16 (+1.68%)
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CRL : 230.16 (+1.68%)
3 Reasons Growth Investors Will Love Charles River (CRL)

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

CRL : 230.16 (+1.68%)
Charles River: 3Q Earnings Snapshot

WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Thursday reported third-quarter profit of $102.9 million.

CRL : 230.16 (+1.68%)
Charles River Laboratories Announces Third-Quarter 2020 Results

--- Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 -

CRL : 230.16 (+1.68%)
Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CRL : 230.16 (+1.68%)
Charles River Laboratories Adds George Llado to Board of Directors

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to its...

ALXN : 123.83 (+0.73%)
CRL : 230.16 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused...

See More

Key Turning Points

2nd Resistance Point 232.89
1st Resistance Point 231.52
Last Price 230.16
1st Support Level 227.43
2nd Support Level 224.71

See More

52-Week High 257.88
Last Price 230.16
Fibonacci 61.8% 195.88
Fibonacci 50% 176.73
Fibonacci 38.2% 157.58
52-Week Low 95.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar